B-Cell Leukemia – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘B-Cell Leukemia – Drugs In Development, 2023’, provides an overview of the B-Cell Leukemia pipeline landscape.
The report provides comprehensive information on the therapeutics under development for B-Cell Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Leukemia and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of B-Cell Leukemia
- The report reviews pipeline therapeutics for B-Cell Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Leukemia therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Leukemia
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AB Science SAAbbVie Inc
Achelois BioPharma Inc
Aleta Biotherapeutics Inc
Allarity Therapeutics Inc
Allife Medical Science and Technology Co Ltd
Amgen Inc
Ascentage Pharma Group International
AstraZeneca Plc
Athenex Inc
Autolus Therapeutics Plc
AVM Biotechnology LLC
Baylor College of Medicine
BeiGene Ltd
Beijing Boren Hospital
Beijing Immunochina Pharmaceuticals Co Ltd
BioInvent International AB
Biosplice Therapeutics Inc
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
California Institute for Biomedical Research
Changchun Institute of Biological Products Co Ltd
Chengdu USino Technology Biology Co Ltd
China Immunotech Co Ltd
Chongqing Precision Biotech Co Ltd
City of Hope
CRISPR Therapeutics AG
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
Enterome Bioscience SA
Eureka Therapeutics Inc
F. Hoffmann-La Roche Ltd
FamiCordTx SA
Gansu Provincial Cancer Hospital
General Hospital of the People's Liberation Army
Gilead Sciences Inc
GT Biopharma Inc
Hangzhou Hezheng Pharmaceutical Co Ltd
HCW Biologics Inc
Henan University of Traditional Chinese Medicine
Huazhong University of Science & Technology
Immunotech Biopharm Ltd
Incyte Corp
ITabMed Co Ltd
Jecho Biopharmaceuticals Co Ltd
Kecellitics Biotech Co Ltd
KK Women's and Children's Hospital
Loxo Oncology Inc
MacroGenics Inc
ManysmarT Therapeutics Inc
Mayo Clinic
Mediolanum farmaceutici SpA
Merck & Co Inc
Mustang Bio Inc
National Cancer Institute US
Neomics Pharmaceuticals LLC
Nkarta Inc
Novartis AG
Ohio State University Comprehensive Cancer Center
PLA Joint Logistics Support Force Hospital 920
Pure Biologics SA
Qilu Cell Therapy Technology Co Ltd
Regeneron Pharmaceuticals Inc
Second Military Medical University
Shanghai Genbase Biotechnology Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shenzhen Geno-Immune Medical Institute
Shenzhen Second People's Hospital
Sorrento Therapeutics Inc
T-Knife GmbH
The First Affiliated Hospital of Nanjing Medical University
Third Military Medical University Hospital One
Tongji University
University of Toledo
Uppsala University
Wuhan Bio-Raid Biotechnology Co Ltd
Xi'An Yufan Biotechnology Co Ltd
Xinqiao Hospital
Xuzhou Medical College
Xuzhou Medical University
Xynomic Pharmaceuticals Holdings Inc